Serendex Pharmaceuticals A/S (OSE: SENDEX) has been granted permission from Oslo Stock Exchange to delist from Oslo Axess as of 4 May 2016. Following this decision, Serendex terminates its market making agreement with NORNE A/S.

Following the Serendex Extraordinary General Meeting in February 2016, Serendex applied Oslo Stock Exchange to be delisted from Oslo Axess.

Today, Oslo Stock Exchange announced that its delisting committee has decided to accommodate Serendex's wish. The last day of listing will be 3 May 2016. Hence, as of 4 May 2016, Serendex Pharmaceuticals will no longer be a listed company.

Read notice about delisting from Oslo Stock Exchange

'The delisting initiative was motivated by the fact that several potential strategic partners during the past year had given us clear feedback that they could only see strategic partnerships develop in a scenario in which Serendex had given up its listing. Against this background, we believe that the chances of securing sustainable funding going forward are significantly increased as a delisted company', says Serendex CEO, Mr. Kim Arvid Nielsen.

Following the delisting, Serendex has also taken measures to terminate its market making agreement with NORNE Securities A/S. Last day of market making will be 29 April 2016.

For download 7 March 2016 Serendex to delist from OSE
Please also read: Q&A about delisting

For further information, please contact:

Nadia Vega Vasiljev
Head of Communication and IR
Mobile +45 2014 9615
E-mail: nvv@serendex.com

Kim Arvid Nielsen
CEO
Mobile +45 2143 1017
E-mail: kan@serendex.com

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess. Please visitwww.serendex.com to learn more.

Serendex Pharmaceuticals A/S issued this content on 07 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 March 2016 13:58:25 UTC

Original Document: http://www.serendex.com/serendex-to-delist-from-oslo-axess-serendex-to-terminate-market-making-agreement-with-norne-as/